The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2021 | Myeloma Patients Europe: collaborating on projects to benefit the myeloma community
The Horizon 2020 CARAMBA project consortium investigates SLAMF7-CAR T-cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the role of Myeloma Patients Europe (MPE) in the CARAMBA project, which includes capturing patients’ needs, values, and experiences. Ms Plate outlines another project within the European Commission’s Horizon 2020 program that MPE are involved in – the MMPredict. Additionally, MPE participates in public-private partnerships such as the Innovative Medicines Initiative (IMI). This interview took place during the 3rd European CAR T-cell Meeting.
Disclosures
Myeloma Patients Europe receives funding from most of the pharmaceutical companies developing myeloma and AL amyloidosis drugs. Ananda Plate has no personal disclosures.
